NEW YORK: There have been several important developments in the psychedelics market in recent years that indicate a change in public sentiment around such products.
For example, earlier this year, billionaires attending the World Economic Forum in Davos heard a pitch from a company developing a psychedelic drug to treat opioid addiction.
In a report by Bloomberg from earlier this January, the Company Atai, backed by billionaire investor Peter Thiel, and partner DemeRx Inc., are preparing for a mid-stage trial of a synthetic form of the substance, called ibogaine, for treatment of drug addiction.
Interest in such therapies is high as an opioid epidemic rages on in the U.S., the German firm's founder Christian Angermayer said in the Swiss ski resort. In some circles, psychedelics are still associated with escape from the real world and irresponsible extravagance, Thiel said in an email according to the report. With FDA-controlled studies, we will come to see that their most powerful use brings people to mental health and sober sanity in a medical setting. The substance, ibogaine, has already been used in some drug rehabilitation clinics to treat addiction. Newleaf Brands Inc. (OTC NLBIF) (CSE NLB), Village Farms International, Inc. (NASDAQ VFF) (TSX VFF), Amyris, Inc. (NASDAQ AMRS), The Supreme Cannabis Company, Inc. (OTC SPRWF), Trulieve Cannabis Corporation (OTC TCNNF)
The path that psychedelics are taking to de-regulation is reminiscent to that of cannabis. Over the past several years, the cannabis industry has reached several milestones to almost completely redefine itself. Now, medical cannabis is predominantly being used to alleviate symptoms associated with afflictions such as chronic pain, cancer, and epilepsy. The positive data has even led many U.S. states to legalize medical cannabis. And as of 2019, there were 33 states and the District of Columbia that have already moved to legalize medical cannabis. An important moment for the industry happened when the U.S. passed the Farm Bill in 2018 which essentially federally legalized hemp-derived CBD products. Shortly afterward, many retailers began to stock CBD products on shelves as well as on their e-commerce platforms. And now, as the cannabis industry continues to expand, it is expected that technology will play a pivotal role in the development of the industry.
Newleaf Brands Inc. (OTC NLBIF) (CSE NLB) announced yesterday breaking news that, it has officially appointed Dr. Aubrey Oliver ND, RBT to be its newest advisor. Dr. Oliver is a Jamaican registered Functional Holistic doctor and a graduate of Ashford University in Complementary and Alternative Medicine.
In recent years, Dr. Oliver was the Coordinating Physician with Caribbean Clinical Research Associates on the first clinical research of its kind which dealt with CBD oil, nano liposome, and alcohol-based forms to find out the absorbency efficacy on healthy cells. Additionally, Dr. Oliver is a certified bioenergetics therapist for cell regeneration and rejuvenation while activating the patient's own stem cells. He is a healing arts specialist with an interest in cannabis and phytonutrients and focuses on a holistic approach towards adrenal exhaustion and aging issues, oncology, infectious diseases and biotoxin illnesses, as well as blood sugar and blood pressure issues.
Damon Michaels, Co-founder of Mydecine and COO of NewLeaf, remarked, We believe working with Dr. Oliver is going to help us expand the cutting edge of Mydecine in many ways. With Dr. Oliver's extensive knowledge for treating people with homeopathic medicine, developing research groups, and understanding unique route administration, we will be able to take the fungi formulations in development to a whole new level.
Dr. Oliver is a strong, well-known member of the Jamaican community and will be working with Mydecine to find ways for the Company to expand its efforts into the Caribbean nation.
Dr. Oliver remarked, 'I'm grateful and humbled to be announced as an advisor with Newleaf Brands. Over the years, I have been looking for the right vehicle to be able to make a powerful healing impact on my beloved island nation of Jamaica. When I understood the path that Newleaf Brands was going down to advance medicine in order to help many, it was a no brainer for me to join this innovative group. I am happy to now be a key asset to contribute to developing things like a treatment facility and setting up a program for patients and clinicians in our beautiful paradise.'